NCT02314143View on ClinicalTrials.gov

Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib

PHASE2TerminatedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 13, 2013

Primary Completion Date

January 19, 2017

Study Completion Date

January 19, 2017

Conditions
Melanoma
Interventions
DRUG

Dabrafenib

Dabrafenib will be provided as 50 mg and 75 mg capsules.

DRUG

Trametinib

Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets.

Trial Locations (7)

13385

GSK Investigational Site, Marseille

28041

GSK Investigational Site, Madrid

33075

GSK Investigational Site, Bordeaux

35042

GSK Investigational Site, Rennes

51092

GSK Investigational Site, Reims

94805

GSK Investigational Site, Villejuif

08036

GSK Investigational Site, Barcelona

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02314143 - Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib | Biotech Hunter | Biotech Hunter